Arrivent Biopharma Inc SEC Filings

OrbiMed filed Amendment No. 1 to its Schedule 13D regarding ArriVent BioPharma common stock to report a change in beneficial ownership after an increase in shares outstanding. The amendment discloses an aggregate beneficial ownership of 3,027,328 shares, representing approximately 7.5% of the 40,568,944 outstanding shares reported in ArriVent's Quarterly Report. The filing clarifies that OrbiMed Private Investments VIII, LP and OrbiMed Asia Partners IV, L.P. each hold 1,513,664 shares (about 3.7% each) and that OrbiMed Advisors, GP VIII, OAP GP IV and Advisors IV have shared or sole voting and dispositive power over those positions.

The Reporting Persons state the shares were acquired for investment purposes and not to obtain control, and confirm they have no current plans to pursue extraordinary transactions or board changes. The filing also summarizes an Amended and Restated Investors' Rights Agreement that provides demand registration rights (requests for S-1 registrations exceeding $20 million), Form S-3 registration rights (thresholds including $5 million and certain percentage holders) and piggyback registration rights, and notes that director Carl L. Gordon is a board member and may receive equity awards subject to transfer obligations to the OrbiMed entities.

ArriVent BioPharma (AVBP) is shown in this Schedule 13G/A as having substantial stakes held by Suvretta Capital Management, LLC and related parties. Suvretta and Aaron Cowen each report shared beneficial ownership of 3,412,788 shares, representing 9.9% of the company’s common stock, while Averill Master Fund, Ltd. reports 2,969,098 shares or 8.7%. All reported shares are held with shared voting and shared dispositive power; none of the reporting persons claim sole voting or sole dispositive power.

The filing states that the securities are directly owned by advisory clients of Suvretta (with Averill identified separately) and includes a certification that the holdings were not acquired to change or influence control. Exhibits listed include a joint filing agreement and control-person identification.

ArriVent BioPharma, Inc. is reported as having a significant passive stake held by related Infinitum entities. The filing shows Infinitum Cayman Master Ltd, Infinitum Asset Management LLC and Infinitum Partners GP, LLC each beneficially own 3,418,923 shares, representing 9.99% of the company’s common stock, and each reports sole voting and sole dispositive power over those shares. The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The disclosure identifies the three reporting entities as the holders and confirms the position is a material passive stake.

ArriVent BioPharma (AVBP) is a clinical-stage biotech focused on firmonertinib and ADC programs. The company reported strong liquidity with $112.8M cash and $141.7M marketable securities (total ~$254.5M), and completed equity raises including $81.9M from an ATM program and a subsequent $81.1M underwritten offering, and has an undrawn $75M term loan commitment.

Operations show increasing investment in development: a $95.8M net loss and $94.1M net cash used in operating activities for the six months reported, driven by $89.0M of R&D spend and growing G&A. Clinical interim data for firmonertinib cited high response rates (e.g., 79% ORR in one cohort and durable responses; FURTHER interim: 16.0 months PFS and 14.6 months DOR at 240 mg), supporting continued development. The company holds substantial contingent milestone and royalty obligations under its licenses (e.g., up to $765M to Allist and ~$1.17B to Lepu).

ArriVent BioPharma, Inc. disclosed that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company furnished that press release as Exhibit 99.1 to this Form 8-K, and also included a Cover Page Interactive Data File as Exhibit 104. The filing states the press release and related information are being furnished and are not to be deemed "filed" under the Securities Exchange Act.

The Form 8-K itself does not include the financial figures or operating metrics; the substantive results are contained in the press release referenced as Exhibit 99.1.